AnaptysBio 将来の成長

Future 基準チェック /36

AnaptysBio利益と収益がそれぞれ年間21.1%と20.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に78.6% 32.7%なると予測されています。

主要情報

21.1%

収益成長率

32.74%

EPS成長率

Biotechs 収益成長	23.0%
収益成長率	20.2%
将来の株主資本利益率	78.62%
アナリストカバレッジ	Good
最終更新日	10 Dec 2025

今後の成長に関する最新情報

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 08

Recent updates

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Nov 13

AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up

Jul 16

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now

Jun 11

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 08

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?

May 07

AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Apr 03

AnaptysBio: A Shadow Of Its Former Self

Mar 06

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Feb 14

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

Dec 18

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Nov 21

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Nov 07

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

業績と収益の成長予測

NasdaqGS:ANAB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	264	-90	-94	-305	7
12/31/2027	168	-189	-39	-97	8
12/31/2026	127	-131	-73	-48	10
12/31/2025	205	-39	-24	-62	10
9/30/2025	169	-85	-145	-145	N/A
6/30/2025	123	-133	-128	-128	N/A
3/31/2025	112	-141	-109	-109	N/A
12/31/2024	91	-145	-136	-135	N/A
9/30/2024	57	-166	-103	-103	N/A
6/30/2024	30	-170	-130	-129	N/A
3/31/2024	23	-163	-134	-133	N/A
12/31/2023	17	-164	-122	-121	N/A
9/30/2023	15	-148	-98	-97	N/A
6/30/2023	13	-144	-79	-78	N/A
3/31/2023	11	-137	-78	-77	N/A
12/31/2022	10	-129	-74	-74	N/A
9/30/2022	4	-135	-88	-88	N/A
6/30/2022	24	-108	-78	-77	N/A
3/31/2022	53	-76	-45	-44	N/A
12/31/2021	63	-58	-47	-46	N/A
9/30/2021	122	8	15	17	N/A
6/30/2021	101	-9	5	7	N/A
3/31/2021	71	-30	-23	-22	N/A
12/31/2020	75	-20	-15	-14	N/A
9/30/2020	18	-74	-68	-68	N/A
6/30/2020	18	-81	-73	-73	N/A
3/31/2020	23	-84	-69	-69	N/A
12/31/2019	8	-97	-70	-70	N/A
9/30/2019	5	-94	-67	-66	N/A
6/30/2019	10	-79	N/A	-59	N/A
3/31/2019	5	-69	N/A	-52	N/A
12/31/2018	5	-62	N/A	-49	N/A
9/30/2018	8	-52	N/A	-41	N/A
6/30/2018	3	-45	N/A	-30	N/A
3/31/2018	10	-34	N/A	-24	N/A
12/31/2017	10	-30	N/A	-19	N/A
9/30/2017	10	-27	N/A	-20	N/A
6/30/2017	13	-19	N/A	-19	N/A
3/31/2017	12	-15	N/A	-15	N/A
12/31/2016	17	-4	N/A	-9	N/A
9/30/2016	18	-4	N/A	-6	N/A
6/30/2016	19	-4	N/A	-5	N/A
3/31/2016	18	-6	N/A	-9	N/A
12/31/2015	18	-5	N/A	-10	N/A
9/30/2015	17	-2	N/A	-6	N/A
6/30/2015	19	0	N/A	-4	N/A
3/31/2015	18	1	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ANAB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANAB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ANAB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANABの収益 ( 20.2% ) US市場 ( 10.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: ANABの収益 ( 20.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ANABの自己資本利益率は、3年後には非常に高くなると予測されています ( 78.6 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/01/02 17:23
終値	2026/01/02 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

AnaptysBio, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。21

アナリスト	機関
Neena Bitritto-Garg	Baird
Etzer Darout	Barclays
Michael King	Citizens JMP Securities, LLC

AnaptysBio 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target decreased by 7.3% to US$45.40

Price target increased by 11% to US$45.55

Price target increased by 9.2% to US$41.09

Consensus revenue estimates increase by 24%, EPS downgraded

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Consensus revenue estimates increase by 16%

Recent updates

Chief Legal Officer notifies of intention to sell stock

Independent Director recently sold US$193k worth of stock

AnaptysBio, Inc. Files a Verified Complaint in Delaware Chancery Court, Requesting a Court Declaration That TESARO, Inc

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints At Week 12 in Moderate-To-Severe Ulcerative Colitis

AnaptysBio, Inc. Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

AnaptysBio, Inc. Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-End 2026

Lead Independent Director exercised options and sold US$130k worth of stock

Price target decreased by 7.3% to US$45.40

New major risk - Negative shareholders equity

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$45.55

AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up

Lead Independent Director exercised options and sold US$348k worth of stock

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now

Anaptys Announces Positive Rosilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Price target increased by 9.2% to US$41.09

Consensus revenue estimates increase by 24%, EPS downgraded

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc., Annual General Meeting, Jun 17, 2025

AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Consensus revenue estimates increase by 16%

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $75 million worth of its shares.

Consensus revenue estimates increase by 14%

AnaptysBio: A Shadow Of Its Former Self

New minor risk - Shareholder dilution

Price target increased by 7.9% to US$37.09

Full year 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Anaptys Announces Rosnilimab Achieves Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response over 6 Months

Independent Director exercised options to buy US$636k worth of stock.

President exercised options and sold US$288k worth of stock

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

Price target decreased by 14% to US$47.90

Anaptys Announces Phase 2B Trial of ANB032, A Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Lead Independent Director exercised options and sold US$181k worth of stock

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Consensus revenue estimates increase by 70%

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Chief Legal Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Consensus revenue estimates fall by 20%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to US$48.22

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock